Tags

Type your tag names separated by a space and hit enter

Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects.
Arterioscler Thromb Vasc Biol 2007; 27(6):1411-6AT

Abstract

BACKGROUND

To explore potential interrelationships between lipoprotein-associated phospholipase A2 (Lp-PLA2), the metabolic syndrome (MetS), and incident cardiovascular disease (CVD).

METHODS AND RESULTS

MetS was defined by the National Cholesterol Education Program Adult treatment Panel III criteria in 4480 nondiabetic Malmö Diet and Cancer Study subjects without history of CVD. Incidence of first CVD event (stroke [130 cases] or myocardial infarction [131]) was monitored over 10 years of follow-up. Lp-PLA2 activity and mass were significantly higher in subjects with MetS. Lp-PLA2 activity compared with Lp-PLA2 mass was more strongly correlated to individual components and increased more linearly with number of MetS components. Elevated Lp-PLA2 activity (top compared with bottom tertile), but not elevated Lp-PLA2 mass, increased risk for incident CVD (relative risk, RR: 1.54, 95% CI 1.07 to 2.24), as did MetS (1.42, 1.06 to 1.90) after taking possible confounders into account. Relative to those without either elevated Lp-PLA2 activity or MetS, combination of MetS and elevated Lp-PLA2 activity increased risk for CVD (1.97, 1.34 to 2.90). Elevated Lp-PLA2 activity without MetS increased risk for CVD (1.40, 1.03 to 1.92) but not MetS without elevated Lp-PLA2 activity (1.46, 0.94 to 2.27).

CONCLUSION

Lp-PLA2 is associated to the MetS. Higher plasma levels of Lp-PLA2 increased risk for incident CVD regardless of MetS. The simultaneous presence of elevated Lp-PLA2 activity and MetS may identify an especially high risk individual.

Authors+Show Affiliations

Department of Clinical Sciences, Internal Medicine Research Group, University Hospital Malmö, Entrance 33, level 2, SE-205 02 Malmö, Sweden. margaretha.m.persson@skane.seNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

17431184

Citation

Persson, Margaretha, et al. "Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome On Incidence of Cardiovascular Events Among Middle-aged Nondiabetic Subjects." Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 27, no. 6, 2007, pp. 1411-6.
Persson M, Hedblad B, Nelson JJ, et al. Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arterioscler Thromb Vasc Biol. 2007;27(6):1411-6.
Persson, M., Hedblad, B., Nelson, J. J., & Berglund, G. (2007). Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. Arteriosclerosis, Thrombosis, and Vascular Biology, 27(6), pp. 1411-6.
Persson M, et al. Elevated Lp-PLA2 Levels Add Prognostic Information to the Metabolic Syndrome On Incidence of Cardiovascular Events Among Middle-aged Nondiabetic Subjects. Arterioscler Thromb Vasc Biol. 2007;27(6):1411-6. PubMed PMID: 17431184.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Elevated Lp-PLA2 levels add prognostic information to the metabolic syndrome on incidence of cardiovascular events among middle-aged nondiabetic subjects. AU - Persson,Margaretha, AU - Hedblad,Bo, AU - Nelson,Jeanenne J, AU - Berglund,Göran, Y1 - 2007/04/12/ PY - 2007/4/14/pubmed PY - 2007/6/15/medline PY - 2007/4/14/entrez SP - 1411 EP - 6 JF - Arteriosclerosis, thrombosis, and vascular biology JO - Arterioscler. Thromb. Vasc. Biol. VL - 27 IS - 6 N2 - BACKGROUND: To explore potential interrelationships between lipoprotein-associated phospholipase A2 (Lp-PLA2), the metabolic syndrome (MetS), and incident cardiovascular disease (CVD). METHODS AND RESULTS: MetS was defined by the National Cholesterol Education Program Adult treatment Panel III criteria in 4480 nondiabetic Malmö Diet and Cancer Study subjects without history of CVD. Incidence of first CVD event (stroke [130 cases] or myocardial infarction [131]) was monitored over 10 years of follow-up. Lp-PLA2 activity and mass were significantly higher in subjects with MetS. Lp-PLA2 activity compared with Lp-PLA2 mass was more strongly correlated to individual components and increased more linearly with number of MetS components. Elevated Lp-PLA2 activity (top compared with bottom tertile), but not elevated Lp-PLA2 mass, increased risk for incident CVD (relative risk, RR: 1.54, 95% CI 1.07 to 2.24), as did MetS (1.42, 1.06 to 1.90) after taking possible confounders into account. Relative to those without either elevated Lp-PLA2 activity or MetS, combination of MetS and elevated Lp-PLA2 activity increased risk for CVD (1.97, 1.34 to 2.90). Elevated Lp-PLA2 activity without MetS increased risk for CVD (1.40, 1.03 to 1.92) but not MetS without elevated Lp-PLA2 activity (1.46, 0.94 to 2.27). CONCLUSION: Lp-PLA2 is associated to the MetS. Higher plasma levels of Lp-PLA2 increased risk for incident CVD regardless of MetS. The simultaneous presence of elevated Lp-PLA2 activity and MetS may identify an especially high risk individual. SN - 1524-4636 UR - https://www.unboundmedicine.com/medline/citation/17431184/Elevated_Lp_PLA2_levels_add_prognostic_information_to_the_metabolic_syndrome_on_incidence_of_cardiovascular_events_among_middle_aged_nondiabetic_subjects_ L2 - http://www.ahajournals.org/doi/full/10.1161/ATVBAHA.107.142679?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -